Bone Biologics Corporation

NASDAQ (USD): Bone Biologics Corporation (BBLG)

Last Price

1.30

Today's Change

-0.05 (3.70%)

Day's Change

1.29 - 1.36

Trading Volume

58,814

Profile
BBLG

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Jeffrey Frelick Mr. Jeffrey Frelick

Full Time Employees:  2 2

IPO Date:  2021-10-13 2021-10-13

CIK:  0001419554 0001419554

ISIN:  US0980705018 US0980705018

CUSIP:  098070303 098070303

Beta:  0.70 0.70

Last Dividend:  0.00 0.00

Dcf Diff:  -15.83 -15.83

Dcf:  19.80 19.80

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Address

2 Burlington Woods Drive,
Burlington, MA 01803, US

781 552 4452

http://www.bonebiologics.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment